SPDR S&P Pharmaceuticals ETF
XPH
XPH
71 hedge funds and large institutions have $105M invested in SPDR S&P Pharmaceuticals ETF in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 22 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
44% less call options, than puts
Call options by funds: $839K | Put options by funds: $1.51M
Holders
71
Holding in Top 10
–
Calls
$839K
Puts
$1.51M
Top Buyers
| 1 | +$10.4M | |
| 2 | +$1.93M | |
| 3 | +$1.81M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$336K |
| 5 |
Two Sigma Investments
New York
|
+$286K |
Top Sellers
| 1 | -$4.6M | |
| 2 | -$2.67M | |
| 3 | -$2.2M | |
| 4 |
LPL Financial
San Diego,
California
|
-$2.03M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.35M |